Douglas W. House, SA News Ed...
•AstraZeneca (AZN -2%) launches Movantik (naloxegol) in the U.S., a once-daily oral medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
•Opioids work by binding to mu-receptors in the brain and other parts of the central nervous system. Unfortunately, mu-receptors also exist in the bowel which leads to OIC. Movantik is mu-opioid receptor antagonist.
•Movantik will be co-promoted in the U.S. by Daiichi Sankyo (OTCPK:DSNKY).
•Previously: AstraZeneca inks U.S. co-commercialization deal for OIC med (March 19)
•Related tickers: (NKTR -1%)(PGNX +0.5%)(CBST)(SLXP +0.1%)(SGYP -2.4%)